COST-EFFECTIVENESS OF NAVIGATED RADIOFREQUENCY ABLATION FOR HEPATOCELLULAR CARCINOMA IN CHINA

被引:3
|
作者
Lai, Yizhen [1 ]
Li, Kai [2 ]
Li, Junbo [3 ]
Liu, Sheena Xin [4 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[2] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou 510275, Guangdong, Peoples R China
[3] Philips Res Asia, Shanghai 200233, Peoples R China
[4] Philips Res North Amer, Briarcliff Manor, NY 10510 USA
关键词
Cost-effectiveness; Real-time Virtual Sonography; Hepatocellular Carcinoma; Radiofrequency Ablation; Markov model; TIME VIRTUAL SONOGRAPHY; HEPATIC RESECTION; SURGICAL RESECTION; CT;
D O I
10.1017/S0266462314000452
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: Real-time virtual sonography (RVS) is a promising navigation technique for percutaneous radiofrequency ablation (RFA) treatment, especially in ablating nodules poorly visualized on conventional ultrasonography (US). However, its cost-effectiveness has not been established. The purpose of this study is to evaluate the cost-effectiveness of RVS navigated RFA (RVS-RFA) relative to US guided RFA (US-RFA) in patients with small hepatocellular carcinoma (HCC) in China, from the modified societal perspective. Methods: A state-transition Markov model was created using TreeAge Pro (TM) 2012. The parameters used in the model, including natural history of HCC patients, procedure efficacy and related costs, were obtained from a systematic search of literature through PubMed, EMBASE, and Science Citation Index databases. The simulated cohort was patients with solitary, small HCC (<3 cm in diameter) and Child-Pugh class A or B, whose tumors are poorly visualized in B-mode US but clearly detectable by CT or MRI. Results: In this cohort of difficult cases, RVS-RFA was a preferred strategy saving 2,467 CNY ($392) throughout the patient's life while gaining additional 1.4 QALYs compared with conventional US guidance. The results were sensitive to the efficacy of US-RFA and RVS-RFA including complete ablation rate and local recurrence rate, the median survival for patients with progressive HCC, the probability of performing RFA for recurrent HCC, and the cost of RVS navigation, disposable needle or hospitalization. Conclusions: RVS-RFA is a dominant strategy for patients with small HCC unidentifiable in B-mode US, in terms of cost savings and QALYs gained, relative to the conventional US-guided method.
引用
收藏
页码:400 / 408
页数:9
相关论文
共 50 条
  • [41] Radiofrequency Ablation for Hepatocellular Carcinoma in Elderly
    Wang, Shen-Yung
    Chen, Yen-Po
    Liao, Po-Hao
    Liu, Chia-Yuan
    Lin, Ching-Chung
    Chen, Chih-Jen
    Chao, Wen-Chi
    Lin, Jiunn-Chang
    Chen, Ming-Jen
    Wang, Tsang-En
    Wang, Horng-Yuan
    Shih, Shou-Chuan
    INTERNATIONAL JOURNAL OF GERONTOLOGY, 2020, 14 (01) : 51 - 55
  • [42] Radiofrequency Ablation for Subcapsular Hepatocellular Carcinoma
    Ronnie Tung-Ping Poon
    Kelvin Kwok-Chai Ng
    Chi-Ming Lam
    Victor Ai
    Jimmy Yuen
    Sheung-Tat Fan
    Annals of Surgical Oncology, 2004, 11 : 281 - 289
  • [43] Radiofrequency thermal ablation of hepatocellular carcinoma
    Allgaier, HP
    Galandi, D
    Zuber, I
    Blum, HE
    DIGESTIVE DISEASES, 2001, 19 (04) : 301 - 310
  • [44] Radiofrequency thermal ablation of hepatocellular carcinoma
    Livraghi, Tito
    Lazzaroni, Sergio
    Meloni, Franca
    European Journal of Ultrasound, 2001, 13 (02) : 159 - 166
  • [45] Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom
    McKenna, C.
    Palmer, S.
    Rodgers, M.
    Chambers, D.
    Hawkins, N.
    Golder, S.
    Van Hout, S.
    Pepper, C.
    Todd, D.
    Woolacott, N.
    HEART, 2009, 95 (07) : 542 - 549
  • [46] COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA
    Xiao, D.
    Zhu, S.
    Sun, W.
    Xuan, J.
    VALUE IN HEALTH, 2019, 22 : S187 - S188
  • [47] Cost-effectiveness of Sorafenib for Treatment of Advanced Hepatocellular Carcinoma in India
    Gupta, Nidhi
    Verma, Rohan K.
    Prinja, Shankar
    Dhiman, Radha K.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2019, 9 (04) : 468 - 475
  • [48] A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment
    Yuen, Sydney C.
    Amaefule, Adaeze Q.
    Kim, Hannah H.
    Owoo, Breanna-Verissa
    Gorman, Emily F.
    Mattingly, T. Joseph I. I. I. I.
    PHARMACOECONOMICS-OPEN, 2022, 6 (01) : 9 - 19
  • [49] Cost-effectiveness of EOB-MRI for Hepatocellular Carcinoma in Japan
    Nishie, Akihiro
    Goshima, Satoshi
    Haradome, Hiroki
    Hatano, Etsuro
    Imai, Yasuharu
    Kudo, Masatoshi
    Matsuda, Masanori
    Motosugi, Utaroh
    Saitoh, Satoshi
    Yoshimitsu, Kengo
    Crawford, Bruce
    Kruger, Eliza
    Ball, Graeme
    Honda, Hiroshi
    CLINICAL THERAPEUTICS, 2017, 39 (04) : 738 - 750
  • [50] Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China
    Shukui Qin
    Eliza Kruger
    Seng Chuen Tan
    Shuqun Cheng
    Nanya Wang
    Jun Liang
    Cost Effectiveness and Resource Allocation, 16